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SOMMARIO/SUMMARY 
 
SOMMARIO/RIASSUNTO 
 
Il carcinoma papillare della tiroide (PTC) è il più frequente tipo di cancro differenziato 
della tiroide, e rappresenta circa l'80% dei casi. Esso ha un’incidenza di circa tre volte 
maggiore nelle donne rispetto agli uomini e rappresenta il settimo cancro per frequenza 
nella donna mentre nell’uomo esso è al quindicesimo posto. Tale aumento di incidenza 
esiste solo durante l’età fertile, difatti dopo gli 80 anni di età, non si evidenzia più una 
differenza per quanto riguarda l’incidenza di questo tumore tiroideo tra i due sessi. 
Recentemente è stato ipotizzato un ruolo degli ormoni sessuali, in particolare degli 
estrogeni, nell’induzione della tumorigenesi per lo sviluppo del cancro tiroideo, ma i 
meccanismi che regolano questi eventi non sono ancora stati ben identificati [1-6].  
I recettori degli steroidi sono caratterizzati da un'elevata affinità e specificità in rapporto ai 
loro leganti. Il recettore dell'estrogeno umano (ER) è una proteina dimerica con peso 
molecolare di 65 kDa, localizzata principalmente sulla membrana del nucleo cellulare e 
appartenente a una classe di proteine attivatrici, che stimolano cioè la trascrizione 
legandosi a elementi specifici del DNA, detti anche elementi di risposta ormonale. 
Legandosi con l'estrogeno, il recettore ER è indotto a stimolare la trascrizione genica; per 
questo motivo è noto anche come fattore enhancer inducibile. 
Studi storici hanno dimostrato che lo stato di ER è correlato direttamente con la prognosi 
(ad es. positivamente nel tumore della mammella invasivo ben differenziato) e alla risposta 
alla terapia anti-ormonale, ad es., tamoxifen. 
È stato riscontrato che gli estrogeni sono principalmente concentrati negli organi bersaglio 
degli estrogeni di animali e nei tumori umani della mammella ed è ben documentato che 
gli effetti mitogenici dell'estrogeno sono mediati dall'ER. Indagini eseguite riguardo i 
meccanismi biologici per la crescita del tumore della mammella hanno dimostrato che la 
velocità della crescita dipende dalla presenza di estrogeni o progesterone o di entrambi in 
gran parte dei tumori della mammella. Pertanto, lo stato del recettore estrogeno nei 
carcinomi mammari è considerato uno strumento di previsione convalidato e un fattore 
predittivo per il trattamento della paziente con terapia anti-ormonale. 
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Lo scopo del nostro studio è stato quello di analizzare i pazienti sottoposti a chirurgia per 
PTC e confrontare le femmine (F) vs i maschi (M) per quanto riguarda le variabili cliniche 
ed istopatologiche per determinare se, come nel carcinoma mammario, vi sono delle 
differenze significative e vi sia effettivamente un ruolo degli estrogeni nella patogenesi del 
PTC. 
In una piccola quota di pazienti è stata valutata la presenza di recettori per gli estrogeni sul 
pezzo operatorio per poter eventualmente identificare anche la possibilità di una terapia 
medica oncologica mirata per questo tipo di tumore. La ricerca di tali recettori è stata fatta 
per valutare quali recettori erano presenti e in che quantità e per determinare se la presenza 
o l’assenza di questi determinava un impatto sulla prognosi. 
Abbiamo considerato 658 pazienti sottoposti a tiroidectomia per PTC dal 2007 al 2011 
presso la Clinica Chirurgica II dell’Università degli Studi di Padova e l’Unità Operativa 
Complessa di Chirurgia Generale dell’Università degli Studi di Trieste. Abbiamo 
analizzato retrospettivamente i dati clinici ed istopatologici e abbiamo confrontato F vs M 
per quanto riguarda le seguenti variabili: età, estensione della chirurgia, tipo di dissezione 
linfonodale, stadi azione sec. TNM, mono/plurifocalità, l’associazione con tiroidite 
cronica, la presenza di mutazione BRAF ed il follow-up. Inoltre nelle donne sono state 
analizzate, l’età del menarca e della menopausa, il numero e l’età delle gravidanze, le 
eventuali interruzioni di gravidanza e la terapia estro-progestinica. Un valore di p inferiore 
a 0.05 è stato considerato statisticamente significativo. 
Di 10 pazienti selezionati abbiamo analizzato il livello di estrogeni nel siero perioperatorio 
e l’espressione dei recettori ER-alpha ed ER-beta mediante studi immunoistochimici per la 
rilevazione semi-quantitativa del recettore dell’estrogeno umano in sezioni di tessuto 
fissate in formalina, incluse in paraffina di tumore della tiroide. 
Questi 10 pazienti, tutte femmine, sono stati suddivisi in due gruppi da cinque in base 
all’età maggiore o minore di 40 anni e questi due gruppi sono stati confrontati tra di loro. 
Confrontando F vs M abbiamo riscontrato una differenza statisticamente significativa per 
quanto riguarda il sesso, difatti le donne sono state il 74% mentre il sesso maschile ha 
rappresentato il 26% dei casi (p < 0,015) e l’associazione con tiroidite cronica autoimmune 
più frequente nelle donne. 
La necessità di eseguire una dissezione linfonodale laterocervicale è stata maggiore nel 
sesso maschile, mentre non è stata riscontrata differenza statisticamente significativa 
riguardo il tasso di recidiva tra i due sessi. 
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Per quel che concerne lo studio del profilo ormonale nelle donne abbiamo riscontrato che 
uno stadio relativamente più avanzato era correlato con un menarca precoce, età più 
avanzata della prima gravidanza e menopausa tardiva. 
Le femmine sono state 489 (74%) vs 169 maschi (26%) (p < 0,015), l'età media è stata di 
46 anni (range 11-86) nelle F vs 46 anni (range 11-83) nei M (p < 0,44). La tiroidectomia 
totale è stata effettuata in 474 F (97%) mentre è stata effettuata in  161 M (95%) (p < 0,72). 
La dissezione linfonodale è stata realizzata in 387 (79%) F vs 132 (78%) M (p < 0,99), La 
linfoadenectomia del compartimento centrale è stata effettuata in 340 (88%) F vs 94 (71%) 
M (p < 0,75) mentre la dissezione laterocervicale è stata eseguita in 47 (12%) F vs 38 
(29%) M (p < 0,011). 
Per quanto concerne la stadiazione: 315 (64%) F vs 87 (51,5%) M (p < 0,19) presentavano 
uno stadio I di neoplasia, 15 (3%) F vs 4 (2,5%) M (p < 0,51) uno stadio II, 126 (26%) F vs 
54 (32%) M (p < 0,24) uno stadio III mentre 33 (7%) F vs 24 (14%) M (p < 0.22) avevano 
uno stadio IV. 
Il tumore era monofocale in 279 (57%) vs F 89 (52,7%) M (p < 0,64), mentre era 
plurifocale in 210 (43%) F vs 80 (47,3%) M (p < 0,76). 
L'associazione con tiroidite cronica autoimmune era presente in 132 F (27%) e 25 M 
(15%) (p < 0,001). Per quanto riguarda la mutazione BRAF, la mutazione V600E è stata 
identificata in 143 (29%) F vs 52 (30,7%) M (p < 0.84). 
Il follow-up è stato possibile in 395 casi. Il tempo medio di follow-up è stato di  37 mesi 
(range 1-343) nelle femmine  rispetto a 45 mesi (range 4-156) nei maschi(p < 0,24). 251 F 
(88%) si sono sottoposte a I
131
radioiodioterapia vs 91 M (83%) (p < 0,74) e la dose media è 
stata di 132.63 mCi (range 50-500) nelle F vs 139.42 mCi (range 50-350) nei M (p < 0,27). 
I livelli medi di Tireoglobulina (Tg) erano 7 mU/L (range 0,1-485.3) nelle F vs 19.83 
(range 0,1-593) nei M (p < 0,11). 274 F (96%) vs 102 M (93.5%) erano libere da malattia 
al follow-up (p < 0,64). Abbiamo riscontrato una differenza statisticamente significativa 
per quel che riguarda il numero di pazienti, la dissezione linfonodale laterocervicale e 
l'associazione con tiroidite cronica autoimmune. 
Riguardo all’espressione dei recettori per gli estrogeni sul pezzo operatorio, sono stati 
studiati 10 pazienti, con un’età media di 48 anni (range: 31-77) Il follow-up medio è stato 
di 3 mesi (range 1-12). 10 preparati chirurgici tiroidei sono stati analizzati con tecnica 
immunoistochimica e sono stati testati gli anticorpi per gli estrogeni alpha e beta.  
I recettori per gli estragoni erano presenti nella maggior parte del campione (80%) e non 
c’erano nel tessuto peritumorale.  
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In conclusione, l’identificazione dei meccanismi di carcinogenesi del PTC nella donna 
rispetto all’uomo rappresenta un passo veramente importante ed innovativo per lo studio 
del carcinoma tiroideo, in particolare il ruolo degli estrogeni nello sviluppo del PTC, una 
volta identificati i precisi meccanismi e steps della tumori genesi, potrebbe aprire la strada, 
come nel cancro mammario, per una potenziale nuova terapia medica antirecettoriale. 
 
 
SUMMARY 
 
Cancer gender disparity in incidence, clinical presentation, disease aggressiveness, and 
prognosis has been observed for a variety of cancers  
The more aggressive types of thyroid cancer, anaplastic thyroid cancer and medullary 
thyroid cancer have similar incidence in men and women. Meanwhile, differentiated 
thyroid cancer of follicular cell origin, such as follicular thyroid cancer and papillary 
thyroid cancer are more common in women. 
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, accounting 
for approximately 80% of cases. Its incidence has nearly doubled over the last 30 years and 
is thought to be due in part to earlier diagnosis of subclinical disease.  
The rate of PTC among woman is nearly three times higher than men but in most studies 
males gender is associated with a lower disease free survival and higher mortality [1-6]. 
Our intention was to consider our experience about the gender disparity in patients 
underwent surgery for PTC comparing females (F) vs males (M) as regards a series of 
clinical, histopathologic, molecular, and hormonal variables to determine if, as in breast 
carcinoma , there is actually a role of estrogens in the pathogenesis of PTC.  
Then, in a little series of patients we evaluated the presence of estrogen receptors on the 
surgical specimen to identify the eventual medical targeted therapy for this type of tumor. 
We considered 658 patients underwent surgery for PTC from 2007 to 2011 at the Institute 
of 2
nd
 Clinical Surgery , University of Padova, and General Surgery Department, 
University of Trieste. We revised clinical and histopathologic documents and we compared 
F vs M as regards the following variables: age, extension of surgery, node dissection, 
TNM, mono/plurifocality, BRAF mutations, and outcome. A p value less than 0.05 was 
considered statistically significant. 
In 10 selected patients, we analyzed the expression of ER- alpha receptors and ER –beta by 
immunohistochemical studies in the sections of formalin-fixed tissue , paraffin-embedded 
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tumor of the thyroid. We have divided patients in two categories:  < 40 years old and > 40 
and then we compared the two groups. 
Comparing F vs M we observed: the F was 489 (74%)  vs  169 M (26%) (p<0.015), the 
mean age was  46 years (range 11-86) in F vs  46 years (range 11-83) in M (p=<0.44), total 
thyroidectomy was realized in 474 F (97%) vs 161 M (95%) (p<0.72), loboistmectomy 
was realized in 13 females (3%) and 8 males (5%) (p<0.83), node dissection was realized 
in 387 (79%) F vs 132 (78%) M (p<0.99), central node dissection in 340 (88%) F vs 94 
(71%) M (p<0.75), laterocervical node dissection in 47 (12%) F vs 38 (29%) M (p<0.011), 
stage I was in 315 (64%) F vs 87 (51.5%) M (p<0.19), stage II in 15 (3%) F vs 4 (2.5%) M 
(p<0.51), stage III in 126 (26%) F vs 54 (32%)M (p<0.249), stage IV in  33 (7%) F vs  24 
(14%) M (p<0.223), monofocality was in 279 (57%)F  vs 89 (52.7%) M (p<0.64), 
plurifocality was in 210 (43%) F vs 80 (47.3%) M (p<0.76), tumor size was 14.13 mm 
(range 0.5-80) , it was 13.97 mm (range 1-80) in F vs 14.62 (range 0.5-70) in M (p<0.42, 
association with thyroiditis was observed in 157 cases, in 132 (27%) F vs 25 (15%) M 
(p<0.001), BRAF – V600E mutation was identified in 143 (29%) F vs 52 (30.7%) M 
(p<0.849). 
We revised the follow up in 395 cases. The mean time of follow up was 37 months (range 
1-343)  in F vs 45 months (range 4-156) in M, 251 (88%) F underwent 
I131radioiodinetherapy vs 91 (83%) M (p<0.74), the median dose was 132.63 mCi  (range 
50-500) in F vs 139.42 mCi (range 50-350) in M (p<0.27), the median time of follow up 
was 37 months in F and 45 months in M (p<0.24),  the median value of Tireoglobulin (Tg) 
was 7 mU/L (range 0.1-485.3) in F vs 19.83 (range 0.1-593) in M (p<0.11), F was free of 
disease in 274 (96%) vs 102 (93.5%) M (p<0.64), 2 patients deceased , 1 was F (0.2%) vs 
1 (1%)M (p<0.24). 
Regarding the expression of estrogen receptors in thyroid tissue, 10 patients, with a median 
age of 48 years (range: 31-77) were analyzed. Mean follow-up time was 3 months (range 
1-12). 10 thyroid glands specimens have been examined using immunohistochemical 
assays with ERs antibodies. We did not find any significant difference in the incidences of 
positive staining for E2 between the two groups.  
There was no expression of antibodies in non-neoplastic cells or in adjacent tissues. 
In conclusion, the identification of mechanisms of carcinogenesis of PTC in women vs 
men is a really important and innovative step for the study of thyroid cancer. 
The estrogen hormones may play an important role as a promoting factor in the 
development of PTC. The role of estrogen in the progress of PTC, once identified the 
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precise mechanisms and steps of tumorigenesis, could open up areas, as in breast cancer, of 
developing potential new medical antireceptorial therapies to prevent and treat thyroid 
malignancies. This indication needs further study. 
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INTRODUCTION 
 
 
Thyroid cancer is the most common and prevalent of all endocrine-based malignancies 
accounting for more than 95% of all endocrine-related cancers [1]. Thyroid carcinomas can 
be classified as two groups based on their morphological variations: the differentiated 
cancers as papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and 
medullary thyroid carcinoma (MTC) and on the other hand undifferentiated cancers as 
anaplastic thyroid carcinoma (ATC) and thyroid lymphoma and sarcoma [1-3].  
PTC and FTC are both classified as differentiated thyroid carcinomas and represent 90–
95% of thyroid cancers [1-3]. PTC, ATC and FTC arise from thyroid follicular cells, while 
MTC arises from C-cells (parafollicular cells). Treating advanced metastatic all thyroid 
cancer remains one of the greatest challenges in cancer research. I
131
 is an effective 
treatment for advanced thyroid cancer; however, its uptake is too low or absent in many 
cases in particular when the cancer is more aggressive and in addition the individual 
responses to radioiodine therapy is highly variable. Therefore, there is a pressing need for 
new treatment options for thyroid cancer and to be able to do so, increased knowledge 
about the biology and pathogenesis of thyroid cancer, as well as the understanding of 
various factors that contribute to thyroid cancer risk and development, is critical. 
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1.1.PAPILLARY THYROID CARCINOMA 
 
Papillary thyroid carcinoma is the most common type of thyroid cancer,[ 1-2] representing 
75 percent to 85 percent of all thyroid cancer cases [3]. It occurs more frequently in 
women and presents in the 20–55 year age group. It is also the predominant cancer type in 
pediatric age, and in patients with thyroid cancer who have had previous radiation to the 
head and neck [4]. 
Lymphatic spread is more common than hematogenous spread and also the multifocality is 
common. 
Although papillary carcinoma has a propensity to invade lymphatics vessels, it is less 
likely to invade blood vessels. These types of tumors are most commonly encapsulated but 
sometimes have more aggressive pattern and may present thyroid capsule invasion. They 
have a high tendency to metastasize locally to cervical lymph nodes, which may produce 
cystic structures near the thyroid that are difficult to diagnose because of the paucity of 
malignant tissue. Furthermore, papillary tumors may metastasize to the lungs and produce 
a few nodules or the lung fields may exhibit a snowflake appearance throughout. 
Moreover, the overall survival is very good but  papillary carcinomas can have also an 
indolent growth, and 40 percent of cases spread out of the capsule. 
Mutations associated with papillary thyroid cancer are mainly two forms of chromosomal 
translocation and one form of point mutation. These alterations lead to activation of a 
common carcinogenic pathway—the MAPK/ERK pathway [2]. 
Among different genetic factors involved in the pathogenesis of the PTC, rearrangements 
of RET protooncogene (RET/PTC), as well as rearrangements of NTRK1 protooncogene 
are best known. The resulting hybrid oncogenes are found in PTCs with variable 
frequency, depending on the examined population. The relationship between these 
chromosomal aberrations and clinical outcome of PTCs remains still controversial. 
Chromosomal translocations involving the RET proto-oncogene (encoding a tyrosine 
kinase receptor that plays essential roles in the development of neuroendocrine cells) 
located on chromosome 10q11 occur in approximately a fifth of papillary thyroid cancers. 
The fusion oncoproteins generated are termed RET/PTC proteins (ret/papillary thyroid 
carcinoma), and constitutively activate RET and the downstream MAPK/ERK pathway 
[2]. 
The frequency of RET/PTC translocations is significantly higher in papillary cancers 
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arising in children and after radiation exposure. The gene NTRK1 (encoding the TrkA 
receptor), located on chromosome 1q, is similarly translocated in approximately 5 percent 
to 10 percent of papillary thyroid cancers [ 2]. 
Approximately a third to a half of papillary thyroid carcinomas harbor point mutations in 
the BRAF oncogene, also activating the MAPK/ERK pathway [ 2]. In those cases the 
BRAF mutations found were V600E mutation. After performing a multivariate analysis, it 
was found that the absence of tumor capsule was the only parameter associated (P=0.0005) 
with BRAF V600E mutation. According to recent studies, papillary cancers carrying the 
common V600E mutation tend to have a more aggressive long term course. BRAF 
mutations are frequent in papillary carcinoma and in undifferentiated cancers that have 
developed from papillary tumors. 
 
 
Figure 1. Papillary Thyroid Carcinoma 
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Papillary thyroid carcinoma is the most common thyroid cancer. About 80% of all 
thyroid cancers cases are papillary thyroid cancer.  
PTC is more common in women than in men. It may occur in childhood, but is most 
often seen in adults between ages 30 and 50. 
The cause of this cancer is unknown. A genetic defect may be involved. 
 
- Risk factors in Papillary Thyroid Carcinoma 
Radiation increases the risk of developing thyroid cancer. Exposure may occur from: 
• High-dose external radiation treatments to the neck, especially during 
childhood, used to treat childhood cancer or some non-cancerous childhood 
conditions 
• Radiation exposure from nuclear plant disasters 
Radiation given through a vein (through an IV) during medical tests and 
treatments does not increase the risk of developing thyroid cancer. 
 
- Clinical presentation of Papillary Thyroid Carcinoma 
Regarding the clinical presentation, papillary carcinoma typically arises as an 
irregular, solid or cystic mass that comes from otherwise normal thyroid tissue. This 
cancer has a high cure rate with 10-year survival rates for all patients with papillary 
thyroid cancer estimated at 80% to 90%. Cervical metastasis are present in 50% of 
small papillary carcinomas and in more than 75% of the larger papillary thyroid 
carcinomas.  
The presence of lymph node metastasis causes a higher recurrence rate but not a 
higher mortality rate.  
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Distant metastasis is uncommon, but lung and bone are the most common sites if the 
papillary carcinoma does spread. Tumors that invade or extend beyond the thyroid 
capsule have a much worse prognosis because of a high local recurrence rate. 
Thyroid cancer usually begins as a small lump (nodule) in the thyroid gland, which is 
located at the center of the front of the neck. 
While some small lumps may be cancer, most (90%) thyroid nodules are harmless and 
are not cancerous. 
Most of the time, there are no other symptoms. 
 
- Characteristics of Papillary Thyroid Carcinoma 
 
 Peak onset ages are 30 to 50 years old 
 Papillary thyroid cancer is more common in females than in males by a 3:1 ratio 
 The prognosis directly related to tumor size (less than 1.5 cm [1/2 inch] is a good 
 prognosis) 
 This cancer accounts for 85% of thyroid cancers due to radiation exposure 
 In more than 50% of cases, it spreads to lymph nodes of the neck 
 Distant spread (to lungs or bones) is uncommon 
 The overall cure rate is very high (near 100% for small lesions in young patients) 
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- Diagnosis of Papillary thyroid carcinoma 
 
Thyroid function tests are usually normal in patients with thyroid cancer. 
The diagnosis is or clinical by palpation of thyroidal mass or by individuation of cervical 
node metastasis. 
The suspicion of cancer presence can be confirmed by cervical ultrasound.  
If the cervical ultrasound shows that the lump is bigger than 1.0 centimeter, a special 
procedure called a fine needle aspiration biopsy (FNAB) will be performed. This test helps 
determine if the thyroid’s nodule or lump is cancerous. 
The management of patients with any thyroid nodules are illustrated in the table 1.
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Table 1. Revised American Thyroid Association Management Guidelines for Patients with 
Thyroid Nodules and Differentiated Thyroid Cancer. THYROID Volume 19, Number 11, 
2009. 
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- Management of Papillary Thyroid Carcinoma 
 
There are three types of thyroid cancer treatment: 
• Surgery 
• Radioactive iodine 
• Medical treatment 
Surgery is done to remove as much of the cancer as possible. 
 
Considerable controversy exists when discussing the surgical management of well-
differentiated thyroid carcinomas (papillary and even follicular). Some Authors 
suggest the hemythyroidectomy one lobe where are located the tumor. Several experts 
and the major Surgical Guidelines contend than if these tumors are small and not 
invading other tissues the intervention indicates is the total thyroidectomy. 
In experienced hands, the incidence of recurrent nerve injury and permanent 
hypoparathyroidism are quite low (about 2%).  
Total thyroidectomy and removal of any enlarged lymph nodes in the central or lateral 
neck areas are the best surgical approach to cure the PTC. 
 
- Major possible complications after surgery:  
• Hypoparathyroidsm or transient or definitive: due to temporary devascularization of 
the parathyroid glands or due to accidental removal of the parathyroid gland which 
helps regulate blood calcium levels 
• Laryngeal (recurrent) nerve palsy: due to damage to a nerve that controls the vocal 
cords 
If surgery is not an option, external radiation therapy can be useful. 
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- Table 2. TNM Staging in Thyroid Carcinoma 
Stage grouping 
Separate stage groupings are recommended for papillary or follicular (differentiated), 
medullary, and anaplastic (undifferentiated) carcinoma  
Papillary and follicular thyroid cancer (age < 45y): 
Stage T N M 
I Any T Any N M0 
II Any T Any N M1 
Papillary and follicular; differentiated (age ≥ 45y): 
Stage T N M 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
IVA T1-3 N1a M0 
T4a N1b M0 
IVB T4b Any N M0 
IVC Any T Any N M1 
Anaplastic carcinoma (all anaplastic carcinomas are considered stage IV): 
Stage T N M 
IVA T4a Any N M0 
IVB T4b Any N M0 
IVC Any T Any N M1 
Medullary carcinoma (all age groups): 
Stage T N M 
I T1 N0 M0 
II T2, T3 N0 M0 
III T1-T3 N1a M0 
IVA T4a N0 M0 
T4a N1a M0 
T1 N1b M0 
T2 N1b M0 
T3 N1b M0 
T4a N1b M0 
T4a N0, N1b M0 
T1-T4a N1b M0 
IVB T4b Any N M0 
IVC Any T Any N M1 
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- Radioactive Iodine therapy in Papillary Thyroid Carcinoma 
Thyroid cells have the cellular mechanism to absorb iodine. The iodine is used by 
thyroid cells to make thyroid hormone. No other cell in the body can absorb or 
concentrate iodine. Physicians can take advantage of this fact and give radioactive 
iodine to patients as a treatment option for papillary thyroid cancer. 
After the surgery, most patients receive radioactive iodine, which is usually taken by 
mouth. This substance kills any remaining thyroid tissue. It also helps make medical 
images clearer, so doctors can see if there is any cancer left behind or if it comes back 
later. 
There are several types of radioactive iodine, with one type being toxic to cells. 
Papillary thyroid cancer cells absorb iodine; therefore, they can be destroyed by 
giving the toxic isotope (I-131). Again, not everyone with papillary thyroid cancer 
needs this treatment, but those with larger tumors, tumors that have spread to lymph 
nodes or other areas, tumors that are aggressive microscopically, and older patients, 
may benefit from this treatment. 
This is an extremely effective type of "chemotherapy" will little or no potential 
downsides (eg, no hair loss, nausea, or weight loss). 
Uptake is enhanced by high thyroid-stimulating hormone (TSH) levels; thus, patients 
should be off thyroid replacement and on a low iodine diet for at least 1 to 2 weeks 
before being treated with radioiodine. It is usually given 6 weeks after surgery. 
 
- Thyroid Hormone Replacement after thyroidectomy for Papillary Thyroid 
Cancer 
Regardless of whether a patient has just one thyroid lobe and the isthmus removed, or 
the entire thyroid gland removed, most experts agree they should be placed on thyroid 
hormone replacement for the rest of their lives. This replaces the hormone in those 
who have no thyroid left, and to suppress further growth of the gland in those with 
some tissue left in the neck. 
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After surgery or radioactive iodine, patients will need to take medication called 
levothyroxine sodium for the rest of their life. This replaces the hormone the thyroid 
would normally make. 
There is good evidence that papillary carcinoma responds to TSH secreted by the 
pituitary, therefore, exogenous thyroid hormone is given, which results in decreased 
TSH levels and a lower impetus for any remaining cancer cells to grow. Recurrence 
and mortality rates have been shown to be lower in patients receiving suppression. 
 
- Long-term Follow-up  in PTC 
Most patients who had thyroid cancer need to have a blood test every 6 - 12 months to 
check thyroid levels. Other follow-up tests that may done after treatment for thyroid 
cancer include: 
• Ultrasound of the thyroid  
• An imaging test called a radioactive iodine (I-131) uptake scan 
In addition to the usual cancer follow up, patients should underwent to serial check of 
thyroglobulin levels. Thyroglobulin is not useful as a screening for initial diagnosis of 
thyroid cancer, but it is quite useful in follow up of a well-differentiated carcinoma (if 
a total thyroidectomy has been performed). A high serum thyroglobulin level that had 
previously been low following total thyroidectomy, especially if gradually increased 
with TSH stimulation, is virtually indicative of recurrence. A value of greater than 10 
ng/ml is often associated with recurrence even if an iodine scan is negative. 
 
- Prognosis of Thyroid Papillary carcinoma 
The survival rate for papillary thyroid cancer is excellent. More than 95% of adults 
with this cancer survive at least 10 years. The prognosis is better for patients who are 
younger than 40 and for those with smaller tumors. 
The following factors may decrease the survival rate: 
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•Age over 45 
•Cancer that has spread to distant parts of the body 
•Cancer that has spread to soft tissue 
•Large tumor 
 
 
24 
 
1.2 GENDER DIFFERENCES IN THYROID CANCER 
 
The gender difference in cancer susceptibility is one of the most consistent findings in 
cancer epidemiology.  
Cancer gender disparity in incidence, clinical presentation, disease aggressiveness, and 
prognosis has been observed for a variety of cancers [1, 5-9]. 
Thyroid cancer is the most common malignancy of the endocrine system and the seventh 
most common malignancy in women, but it is not among the most common 15 cancer in 
men [10,11]. 
The gender disparity in thyroid cancer is also specific to the histologic subtype of thyroid 
cancer. The more aggressive types of thyroid cancer, anaplastic thyroid cancer and 
medullary thyroid cancer have similar incidence in men and women. Meanwhile, 
differentiated thyroid cancer of follicular cell origin, such as follicular thyroid cancer and 
papillary thyroid cancer are more common in women [10,11]. 
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, accounting 
for approximately 80% of cases and its incidence has nearly doubled over the last 30 years 
and is thought to be due in part to earlier diagnosis of subclinical disease [1,5].  
The rate of PTC among woman is nearly three times higher than men but in most studies 
males gender is associated with a lower disease free survival and higher mortality 
[8,10,11]. 
As the incidence of thyroid cancer increases, in particular PTC, the gender differences 
observed are likely to be even more dramatic. 
Hematologic malignancies are generally more common in males and this can be 
generalized to most other cancers. Similar gender differences in non-malignant diseases 
including autoimmunity, are attributed to hormonal or behavioral differences. Even in 
early childhood, however, where these differences would not apply, there are differences in 
cancer incidence between males and females. In childhood, few cancers are more common 
in females, but overall, males have higher susceptibility. In Hodgkin lymphoma, the gender 
ratio reverses toward adolescence. The pattern that autoimmune disorders are more 
common in females, but cancer and infections in males suggests that the known differences 
in immunity may be responsible for this dichotomy. Besides immune surveillance, genome 
surveillance mechanisms also differ in efficiency between males and females. Other 
obvious differences include hormonal ones and the number of X chromosomes. Various 
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risk factors aid in the progression and dissemination of the disease such as age, radiation, 
genetic lesions, iodine deficiency or excess iodine consumption, however the causes of 
most thyroid cancers is yet to be elucidated.  
 
a. Radiation exposure: 
Post-Chernobyl epidemiologic studies have showed that, although the incidence of 
papillary thyroid cancer increased in the exposed population, there was a decrease in the 
female to male ratio. Based on the current evidence, ionizing radiation does not appear to 
play a role in the gender disparity of papillary thyroid cancer, with both genders being at 
equal risk of developing thyroid cancer after exposure. 
 
b. Dietary and nutritional factors: 
Dietary and nutritional factors have been implicated as risk factors for differentiated 
thyroid cancer of follicular cell origin. Iodine deficiency is a well-established risk factor 
for developing follicular thyroid cancer, and iodine supplementation has been implemented 
in most regions with endemic goiter. By contrast, iodine excess has been associated with 
an increased risk of papillary thyroid cancer. Chronic iodine deficiency may have a 
protective effect in females [12], but there are no equivalent studies looking at male 
gender. 
In the San Francisco Bay Area Thyroid Cancer study group, a protective effect of dietary 
iodine and phytoestrogens was found in women, but the study did not have any male 
subjects [13]. The role of fish (high in iodine) and cruciferous vegetables on thyroid 
cancers have been debated. However, there are no studies that show a gender difference in 
the effects of fish and cruciferous vegetables in thyroid cancer. 
 
c. Common somatic genetic changes associated with thyroid cancer 
The three most common types of somatic mutations observed in papillary thyroid cancer 
are rearranged in transformation/papillary thyroid carcinomas (RET/PTC) and 
neurotrophin receptor tyrosine kinase (NTRK)1 rearrangements, and an activation 
mutation in the mitogen signaling protein BRAF. These genetic alterations are present in 
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approximately two-thirds of papillary thyroid cancer and are specific to papillary thyroid 
cancer. The RET/PTC rearrangement is found in 20–40% of adult sporadic papillary 
thyroid cancer. The NTRK rearrangement is less common and it is found in up to 13% of 
papillary thyroid cancer [14,15]. 
The BRAF V600E point mutation accounts for over 97% of the BRAF mutations in 
papillary thyroid cancer. The BRAF mutation is present in approximately 40% of papillary 
thyroid cancer [14,15]. 
 
d. BRAF mutation 
There have been several studies that have demonstrated that the presence of BRAF V600E 
mutation is associated with an aggressive tumor phenotype in papillary thyroid cancer, 
including a larger tumor size, extrathyroidal invasion, poorly differentiated histology, 
lymph node and distant metastases, and it is also associated with older age, higher 
recurrence rates and gender [16]. 
The BRAF (V600E) mutation, the most frequent genetic mutation in papillary thyroid 
carcinoma (PTC), is widely considered to have an adverse impact on PTC outcome 
however its real predictive value is not well stated. 
Xu and colleagues observed that BRAF V600E mutation in men with papillary thyroid 
cancer was 64% compared with 27% in women [16]. In another study of 203 patients with 
papillary thyroid cancer, BRAF V600E mutation was present in 91% of men compared 
with 70% of women [17]. 
Besides, a meta-analysis of twelve studies with a total of 1168 patients (male:female ratio 
259:909) did not show a significant difference in mutation rate by gender, with 50% of the 
males and 49% of the females with papillary thyroid cancer having the BRAF V600E 
mutation [18]. 
 
e. RET/PTC & NTRK rearrangement 
Multiple studies have looked at the association of clinicopathological features of papillary 
thyroid cancer with the presence of this rearrangement. Although the association of 
RET/PTC rearrangements with radiation is well established, there is limited evidence 
supporting any association with tumor phenotype and gender [16,18].  
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Therefore, RET/PTC rearrangement in papillary thyroid cancer does not appear to be 
different by gender. 
 
f. Reproductive factors 
The fluctuation of sex hormones during a woman’s menstrual cycle and pregnancy has 
been hypothesized as the reason for the gender disparity in papillary thyroid cancer. In 
particular, the peak incidence of papillary thyroid cancer has been observed in women aged 
40–49 years, this being the age group at which most women approach or enter menopause 
[19].  
There have been several studies looking at the association of papillary thyroid cancer with 
reproductive factors such as age of menarche, menopause, number of pregnancies and 
other parameters [19-24]. However, the evidence for hormonal, menstrual or reproductive 
roles in thyroid cancer in women is nowadays inconclusive. Late age of menarche, late age 
of first child birth, artificial menopause and miscarriage for the first pregnancy were 
significant in a study conducted by Negri E. et al. [19]. 
The age of menarche, age at menopause, number of pregnancies or oral contraceptive use 
were not associated with a higher risk of developing thyroid cancer. There was no 
association observed with irregular menstrual cycles, history of miscarriage or induced 
abortion, time since last birth, age and 
outcome of first pregnancy or breastfeeding. 
 
g. Sex hormones 
The important role of sex hormones in cancer is well documented for breast and prostate 
cancers. Sex hormone effects are mediated by hormone-specific nuclear receptors that 
regulate gene expression and tumor cell biology. The α- and β-estrogen receptors mediate 
the effect of estrogen and are expressed in papillary thyroid cancer [25]. 
It has been hypothesized that the polymorphism in estrogen receptors could be a risk factor 
for thyroid cancer [26]. Inoue et Al. demonstrated that although papillary thyroid cancer 
cells have low levels of estrogen receptor-α, with physiologic estrogen stimulation the 
receptor level is significantly upregulated and cell proliferation is promoted [27]. 
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Furthermore, estrogen can dramatically increase the rate of cell proliferation in thyroid 
cancer cell lines compared with male sex hormones [25,28]. It also modifies the expression 
of estrogen receptor subtypes in thyroid cancer cell lines [25,28,29]. 
The effects of estrogen on thyroid cancer cell lines are dependent on the histological type 
of thyroid cancer, and estrogen dramatically increases estrogen receptor-α levels in 
papillary thyroid cancer, whereas in anaplastic thyroid cancer and follicular thyroid cancer 
the receptor levels are not significantly altered [28, 29]. The expression of estrogen 
receptor-β in papillary thyroid cancer cells was increased in anaplastic thyroid cancer cell 
lines. In addition, estrogen treatment promoted the growth of papillary thyroid cancer cells 
in culture but inhibited growth in anaplastic thyroid cancer. Rajoria S. et al also 
documented that estrogen is associated with increased adherence, invasion and migration 
in thyroid cancer cell lines [30].  
Based on these in vitro studies, in papillary thyroid cancer, estrogen receptor status is 
affected by sex hormones. This may play a role in the gender disparity observed in 
papillary thyroid cancer, and can serve as a potential target for the treatment of advanced 
papillary thyroid cancer. 
Similar molecular observations have been made during pregnancy. In particular, chorionic 
gonadotropin, which has been demonstrated to have close homology with 
thyroidstimulating hormone, has been shown to cause rapid growth of thyroid tumors 
(benign or malignant) during pregnancy [31,32].  
 
h.  family history of endocrine-related diseases 
Family history of endocrine-related malignancies, such as breast cancer and goiter, are also 
known to predispose one to thyroid cancer.  
According to American Thyroid Association (ATA), the incidences of thyroid proliferative 
diseases (TPD), which includes thyroid cancer, are four to five times more prevalent in 
women than in men [33-36].  
The risk of developing thyroid disorders in women is one in eight which is comparable to 
that of sporadic breast cancer in women, and is significantly enhanced with family history 
of endocrine-related diseases, age, use of oral contraceptives, autoimmune diseases and 
pregnancy [37,38]. With respect to pregnancy, there is approximately 5% chance of 
developing a thyroid disorder in new mothers within 6 months of birth. An increased risk is 
also noted with the use of estrogen for gynecological problems, with a noted decrease in 
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the incidences of thyroid malignancies after menopause [39,40]. Reproductive challenges 
and infertility have all been associated with thyroid hormone abnormalities and the 
goitrogenic effects of iodine are more pronounced in women than in men. This marked 
gender bias in distribution of TPDs, with the incidence of thyroid disorders being much 
higher in women than in men, suggests that being a female might be the highest risk for 
developing TPDs. Indirect effects of estrogen on thyroid hormone synthesis and release 
have been demonstrated in the past [41,42], but the direct effects of estrogen on thyroid 
diseases are still not fully explored.  
Several studies have been performed worldwide in an effort to investigate the role of 
estrogens in various cancers but the precise mechanism for estrogenopathies in TPDs 
remains poorly understood.
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1.3 ESTROGEN AND ITS RECEPTORS 
 
Estrogens play crucial roles in growth, differentiation, and function of not only sexual and 
reproductive organs, but also cardiovascular, musculoskeletal, immune and central nervous 
system in both men and women [43,44]. Estrogens consist of a group of three 
biochemically distinct hormones, estrone, 17 β -estradiol, and estriol, which are produced 
naturally by the female body and are metabolized into estrogen metabolites such as 2-
hydroxyestrone (2-OHE1) and 16-alphahydroxyestrone (16-OHE1) [45,46]. These 
estrogen metabolites have stronger (16-OHE1) or weaker (2-OHE1) estrogenic ability and 
their relative concentration in females can increase the risk of developing breast, uterine 
and other cancers [46,47]. 17 β-estradiol, commonly denoted as E2, is the central and most 
potent player of the estrogens on the human body due to its highest affinity for estrogen 
receptors [48]. 
Estrogen signaling is mediated primarily through two isoforms of the estrogen receptor 
(ER), ER-α & ER-β, which are members of a large ligand dependent nuclear receptor 
superfamily of transcriptional factors [49,50]. Human ER-α protein consists of 595 amino 
acids with a molecular weight of 66 kDa while ER-β protein has 530 amino acids and a 
molecular weight of 55 kDa [51- 53]. The cellular signaling is initiated by binding of 
estrogen to these receptors by at least three different mechanisms, leading to a 
‘multifaceted cascade of events’ [41, 54 ]. Genomic or classical estrogen signaling 
involves entry of estrogen in the target cell via passive diffusion, leading to a 
conformational change(s) of the estrogen receptor. This conformational change allows the 
dissociation of the receptor from its chaperone proteins, followed by nuclear translocation 
and homo- or hetero-dimerization of E2-ER. The complex then binds to a nucleotide 
sequence located in the promoters of target genes, known as estrogen response element 
(ERE). The activated DNA bound ER then recruits transcriptional co-activators resulting in 
an assembly of transcriptional complex and subsequent gene expression. This mechanism 
of E2 action has a slow transcriptional response from hours to days for maximal gene 
activation [55-57 ]. However, one-third of the genes regulated by estrogen in humans do 
not contain ERE-sequences [57,58]. In such cases, estrogen can regulate gene expression 
by modulating the functions of other transcriptional factors in the nucleus, by protein–
protein interactions, leading to alteration of chromatin, histone unwinding and interactions 
with basal transcription machinery complex components and is known as ERE-
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independent genomic actions of estrogen [59]. Estrogen also exerts a variety of cellular 
responses in bone, breast, vasculature and nervous system which are rapid and do not 
depend on E2–ER mediated gene transcription and protein synthesis [59-60]. These actions 
are referred are believed to be mediated through activation of ER located in or adjacent to 
the plasma membrane or through other plasma membrane-associated estrogen binding 
proteins [61,62]. These actions lead to regulation of various genes involved in a wide array 
of cellular processes such as proliferation, differentiation, cell motility and apoptosis [61]. 
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1.4. EXPRESSION OF ESTROGEN RECEPTORS IN THYROID TISSUES 
 
ER-α is predominantly expressed in breast, uterus, cervix, vagina, pituitary and several 
other organs including thyroid, while ER-β is predominantly expressed in ovary, prostate, 
testis, spleen, lung, hypothalamus, thymus. The presence of ER in thyroid was first 
reported in early 1980s using synthetic estrogens as a radioligand and has been since 
reported by several groups including ours in normal thyroid tissues as well as benign and 
malignant thyroid carcinomas [63-66]. ER-α mRNA has also been reported in both non-
neoplastic and neoplastic thyroid tissues. The presence of both ER-α and ER-β in thyroid 
tissue, similar to that observed in breast carcinoma, would suggest that the relative ratio of 
ER-α and ER-β in thyroid carcinoma could have an important role in the pathophysiology 
of thyroid cancer [61,67,68]. The studies of Cho et al. demonstrated an increased ratio of 
ER-α /ER-β in human medullary thyroid cancer validating the contention [69]. 
Furthermore, Zeng et al. observed that the agonist and antagonist for ER-α and ER-β 
regulate the expression levels of the receptors. They demonstrated that ER-α agonist 
propylpyrazole-triol (PPT) enhances thyroid carcinoma proliferation and expression of 
antiapoptotic protein, Bcl-2, while ER-β agonist diarylpropionitrile (DPN) inhibits cell 
proliferation and enhanced the expression of Bax [70]. In addition, siRNA mediated 
knockdown of ER-α significantly attenuated Bcl-2 expression while ER-β silencing 
enhanced Bcl-2 expression [70], further supporting the notion that the imbalance between 
ER-α and ER-β expression may contribute to thyroid cancer pathogenesis. 
Indeed some reports have shown a comparable ER-α expression in normal and tumor 
thyroid tissue [71,72], however all these reports rely on immunohistochemistry (IHC) to 
determine the presence or absence of ER-α expression, and it is therefore interesting to 
note such a difference in the ER-α expression from different laboratories. A recent study 
[73] investigated the possibility of measuring ER-α in PTC samples by different molecular 
biology techniques. The best approach to individuate ER-α expression was found to be 
Laser-capture microdissection (LCMD), followed by real-time PCR or Western blot in the 
study. 
Therefore, the different and opposing results regarding the expression of ER-α in normal 
thyroid tissue could depend, in the case of a whole tissue analysis, on the ratio between 
tumor and normal cells in the sample analyzed. In this study, ER-α expression could be 
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detected in human biopsy specimens obtained from PTC and at much lower level from 
goiter [73]. 
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1.5. EFFECTS OF ESTROGEN ON THYROID HORMONE ACTIVITY 
 
The normal physiological functions of the thyroid gland involve the synthesis and secretion 
of two principal metabolic hormonestriiodothyronine (T3) and thyroxine (T4) and their 
metabolism and action on the peripheral tissue. The mechanism of action for thyroid 
hormones’ activity involves hormone binding to the nuclear thyroid hormone receptor 
(TR), resulting in formation of a complex which then binds to thyroid hormone response 
elements in promoter regions of the target genes. The activated receptor can then either 
stimulate or inhibit transcription of the target gene depending on the nature of regulatory 
element, bringing in effect its various functions. Both ERs and TRs are members of the 
nuclear receptor superfamily and they share an identical half site at the consensus sequence 
of nucleotide bases which constitute ER response element and thyroid hormone response 
element. This allows the TR to bind ERE and vice versa, and such interactions between 
these nuclear receptors can possibly lead to an infinite number of gene regulatory events, 
leading to a greater array of transcriptional response to environmental stimuli. There are 
discrepancies in the literature in regards to effects of estrogen on activation of pituitary-
thyroid axis essential for the normal physiological functions of thyroid gland. 
A study by Banu et al. implicates that the stimulatory effects of estrogen on human NPA-
87-1 papillary thyroid carcinoma are independent of thyroid-stimulating hormone (TSH) 
activity. In this study, they observed that estrogen enhances the proliferation of thyroid 
cells potentially by upregulating the ERs and these proproliferative effects of estrogen 
were independent of TSH administration [74]. Furlanetto et al. demonstrated similar 
proliferative effects of estrogen on rat FRTL-5 thyroid follicular cells which were 
independent of TSH administration. Moreover, they observed that estrogen attenuates 
TSH-induced sodium/ iodide symporter (NIS) expression in the thyroid cells while 
cotreatment with estrogen and fulvestrant restored the TSH induced NIS expression [75]. 
The same group later showed that estrogen treatment led to a decreased iodide uptake from 
the same FRTL-5 thyroid cells [76]. Estrogen may be directly acting on the NIS system 
modulating its ability to carry iodide or may be leading to production of growth factors 
which leads to decreased iodide uptake, but this needs further investigation. Lima et al. 
demonstrated that estradiol administration in prepuberatal and adult rats leads to a 
significant increase in the thyroid weight but they observed no significant changes in 
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serum T3, T4 and TSH levels, suggesting a more direct action of estrogen in the thyroid 
gland [77]. 
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1.6. ESTROGEN ON AND TUMOR PROGRESSION 
 
In a study of Zeng Q et al. [29] it has been investigated how 17beta-oestradiol (E2) 
influenced, promoting the proliferation and growth of thyroid cancer cells. Imbalance 
between ERalpha and ERbeta may contribute to thyroid carcinogenesis. 
Tumor metastases accounts for around 90% of all the cancer related deaths [78 ]. The 
process of metastasis involves sequential steps and the tumoral tissue invades the 
circulation through the process called intravasation. After intravasation, individual tumor 
cells migrate to the distant sites, make transient adhesion to the vessel wall and start 
invading the new organ, a process called extravasation. The last step is colonization of the 
tumor cells at the new site and initiating the formation of new blood vessels–angiogenesis–
allowing them to establish and expand the newly formed metastatic foci [78,79]. 
For reasons still unknown, certain cancer types have a high probability to metastasize 
while others never metastasize. 
Secondary metastatic lesions are a major complication in patients with thyroid cancer. The 
secondary disseminated metastasis causes many patients to relapse despite the improved 
surgical and therapeutic processes, causing further complications. Several factors aid in a 
number of molecular mechanisms involved in the malignant transformation and 
development of metastatic disease, including estrogen. Kousidoua et al. have observed a 
positive correlation between ER-α expression and the effects of estrogen on matrix 
metalloproteinase (MMP) gene expression in ER+ breast cancer cells [80]. Nilsson et al. 
have also shown that estrogen regulates the metastatic propensity in breast cancer by 
regulating the activity of MMP-2 and MMP-9 [81], but there are not much evidences 
linking estrogen with thyroid cancer metastasis. 
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1.7. EFFECTS OF ESTROGEN ON ON THYROID CANCER METASTASIS 
 
Well-differentiated thyroid cancer, including papillary and follicular thyroid cancer, can 
metastasize to the nearby lymph nodes in over 50% of the cases [82,83], with secondary 
disseminated metastasis being the biggest complication in the majority of thyroid cancer 
patients. Rajora S et al has recently shown that estrogen enhances thyroid cancer cell 
adhesion, migration and invasion, potentially due to downregulation of tumor suppressive 
proteins such as catenins and cadherins [66,67]. A defective cadherin/catenin complex has 
been correlated with increased cancer proliferation and progression in vitro and in vivo, 
while restitution of the cadherin/catenin complex has shown to suppress metastasis in 
several cancers including estrogen responsive cancers. Rajora S have recently shown that 
cotreatment with an antiestrogen, fulvestrant, restores catenin protein levels, further 
validating the effects of estrogen on cadherin/catenin proteins in thyroid cancer cells. 
Besides cell–cell adhesion proteins, proteolytic enzymes such as MMPs also play a critical 
role in tumor cell invasion. It was recently demonstrated that estrogen treatment leads to 
enhanced activity and secretion of MMP-2 and MMP-9 in human thyroid cancer cells, 
which was attenuated by ER antagonists [67]. 
Roudabush et al. have demonstrated that activation of ERK1/2 requires the involvement of 
estrogen regulated MMPs in monkey kidney fibroblast COS-7 cells [84]. Later, Song et al. 
demonstrated in human MCF-7 breast cancer cells that estrogen leads to a sequential 
activation of MMPs and MAPK [85]. A study by Ocharoenrat et al. showed that growth 
factors were able to stimulate MMP 9 activation in head and neck squamous cell 
carcinoma and elevated levels of MMPs have been demonstrated in thyroid carcinoma 
[86]. In a later study, Yeh et al. further demonstrated that MMPs act as critical effectors of 
invasion in papillary and follicular thyroid cancer cell lines [87]. A recent study showed 
that silencing of ER-α using siRNA attenuates estrogen-mediated migration and invasion 
of human thyroid cancer cells [67].
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1.8. ANTIESTROGENS AS THERAPEUTIC AGENTS FOR THYROID DISEASES 
 
The observations that thyroid cells are estrogen responsive and estrogen can directly and 
indirectly modulate thyroid cancer proliferation, metastasis and angiogenesis opens up the 
possibility of using antiestrogens. Several antiestrogenic synthetic compounds such as 
tamoxifen and ICI 182,780 (fulvestrant) exists but unfortunately, these compounds have 
undesirable side effects such as ICI 182,780 results in a complete blockade of the 
activation pathways of ER and tamoxifen resulting in detrimental uterotrophic effects and 
can act as an agonist for breast cancer cell growth [88,89]. These damaging effects warrant 
the research for safer alternatives such as natural compounds present in diet, for thyroid 
disease treatment and prevention. 
Many studies has shown that exposure of estrogen responsive cancers, such as breast 
cancer, to I3C and its in vivo dimeric product DIM trigger anti-proliferative and/or 
apoptotic signals [67, 90-94]. 
Despite its beneficial roles, especially against hormone responsive cancers such as thyroid 
and breast, the exact anti-cancer mechanism of DIM has not been fully elucidated. Studies 
indicate that DIM affects estrogen mediated effects on cancer cells by activating several 
individual and interdependent transcriptional, cell signaling, enzymatic and metabolic 
cascades that result in the abrogation of estrogen-induced cell proliferation. A recent study 
by Rajora S group has revealed that DIM acts in a similar fashion to the antiestrogenic 
compound fulvesterant by inhibiting estrogen-induced proliferation and clone formation of 
thyroid cancer cells [67]. DIM was also observed to interfere with essential events 
involved in cancer cell metastasis as evidenced by a decrease in in vitro cell adhesion, 
migration, and invasion [67,95]. Of these three crucial steps involved in initiating 
metastasis, invasion is the most essential one. An agent that could efficiently inhibit the 
ability of cancer cells to form secondary metastatic foci would be an ideal candidate to 
suppress cancer progression. DIM has a unique antiinvasive property, with as high as 78% 
inhibition of invasion observed in papillary thyroid cancer cells. The observed 
antiestrogenic property of DIM is in accordance with its ability to modulate E2–ER 
interactions and E2-mediated signal transduction pathways such as the pAKT and ERK 
pathways, as described earlier by us and others, which provide evidence that DIM shows a 
strong potential for treatment and prevention of thyroid diseases including cancer. 
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AIM OF THE STUDY 
 
Our intention is to consider our experience about the gender disparity in patients 
underwent surgery for PTC comparing females (F) vs males (M) as regards a 
series of clinical, histopathologic, molecular, and hormonal variables to 
determine if, as in breast carcinoma , there is actually a role of estrogens in the 
pathogenesis of PTC.  
Then, we have evaluated the presence of estrogen receptors on the little series of 
surgical specimen to identify the eventual medical targeted therapy for this type 
of tumor. 
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MATERIALS AND METHODS 
 
 
a. Patients selection 
We considered 658 patients underwent surgery for histologically proven Papillary Thyroid 
Carcinoma (PTC) from 2007 to 2011 at 2
nd
 Clinical Surgery, University of Padova, and 
General Surgery Department, University of Trieste.  
The patients were given a detailed explanation of aim of our study  and all patients gave 
their informed consent to participate. 
 
b. Variables evaluated 
We revised clinical and histopathologic documents and we compared F vs M as regards the 
following variables: age, extension of surgery, node dissection, TNM, mono/plurifocality, 
association with limphocitary chronic thyroiditis, BRAF mutations, and outcome. 
 
c. Reproductive factors analysed in women 
In the women, the hormonal variables, as: age of menarche, age and type of menopause, 
number and age of pregnancy, interruption of pregnancy, and the assumption of oral 
estrogen-progestin therapy, were investigated to determine the effective role of 
reproductive factors and hormonal effects in the pathogenesis of this tumor. 
All female patients investigated for the variables cited below, were divided in two groups: 
< 40 years (childbearing) old and age > 40 years old. For each stage the various variables 
were tested to determine if there were any correlation with a specific reproductive factor. 
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d. Evaluation of expression of ER- alpha and ER-beta receptors in thyroid tissue 
In a little series of patients, we prospectively analyzed the perioperative serum level of 
estrogens and the expression of ER-alpha receptors and ER – beta by 
immunohistochemical studies in the sections of formalin-fixed tissue , paraffin-embedded 
tumor of the thyroid. Then, the patients selected, all women, were divided in two groups: 
age < 40 years (childbearing) old and age > 40 years old. These two groups were compared 
regarding stage and outcome. 
 
e. Follow-up evaluation 
At follow up the patients underwent physician exam, thyroid function testing, serum 
Thyroglobulin (Tg) levels, and circulating anti-Tg antibodies, measured 4 weeks after 
operation before levothyroxine suppression therapy. 
The completeness of the operations was determined also by neck US exam and by iodine-
131 (
131
I)  whole body scan (WBS) 3 to 6 months after surgery. 
After total thyroidectomy, the treatment with 
131
I to ablate postsurgical thyroid remnant 
were performed, in hypothyroidism conditions (TSH > 30µUI/mL, obtained by 
withdrawing thyroid replacement hormone), on the basis of  stage and prognostic/risk 
factors according to the American Thyroid Association Guidelines [9]. 
WBS was repeated in these patients 4 days after 
131
I administration to visualize any thyroid 
remnant or metastases, followed by thyroid hormone supplementation. 
The mean period of time elapsed between the thyroidectomy and 
131
I administration for 
postsurgical remnant ablation was 3–4 months. Patients who did not receive radioiodine 
treatment underwent long-term follow-up at 6- to 12-month intervals, at which time 
ultrasonographic examinations were performed, and serum Tg levels were measured while 
the patients were on levothyroxine. Patients whose WBS revealed no thyroid remnants or 
metastases were also placed on this follow-up protocol. The criteria for successful thyroid 
ablation were defined as the disappearance of any visible area of uptake in the thyroid bed 
( ≤ 1%), and undetectable serum Tg levels off  levothyroxine (TSH >30µUI/mL). 
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f. Statistical analysis 
The statistical analysis was performed by using the following tests: the Mann-Whitney test 
for age, and  the χ2 test for gender, surgical procedure/extension of surgery, node 
dissection, TNM, mono/plurifocality, association with thyroiditis, BRAF mutations, and 
outcome. 
The software used was the “Statistica released 7”. 
A p value less than 0.05 was considered statistically significant. 
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RESULTS 
 
Comparing F vs. M there was a statistically significant difference with regard to sex, in 
fact, women were 74% while the male sex accounted for 26% of cases (p <0.015), the 
association with chronic autoimmune thyroiditis (more frequent in women), and the lateral 
cervical lymph node dissection (necessary in most men). 
Comparing females with men regarding the rate of recurrence, we did not find a significant 
difference.  
In our series BRAF
V600E
 mutation was identified in 29% of women and in 30.7% of men 
confirming the absence of significant difference among two sexes. 
In our series, regarding the reproductive factors in the women, relatively more advanced 
stage was correlated with early menarche, older age of first pregnancy, late menopause; 
moreover, a higher incidence of tumor was registered in childbearing age stressing the role 
of estrogen to promoting the PTC. 
Moreover, our data confirm that, comparing males vs females, there was a significant 
difference concerning the number of patients affected by PTC with a preponderance of 
women. Also the number of central node dissection performed was dissimilar among the 
two groups of patients, in fact it was performed  in only 12% of females and in 29% of 
males confirming the major aggressiveness of this tumor in the men. The association with 
thyroiditis was most important in the women confirming the better outcome in female 
gender, whereas the others characteristics as age, TNM stage, mono and plurifocality, 
BRAF mutations, and outcome were not statistically diverse between two sexes.  
Of the 658 patients considered in this study, the F was 489 (74%)  vs  169 M (26%) 
(p<0.015), the mean age was 46 years (range 11-86), in particular 46 years (range 11-86) 
in F vs 46 years (range 11-83) in M (p=<0.44), total thyroidectomy was realized in 635 
cases,  474 F (97%) vs 161 M (95%) (p<0.72), loboistmectomy was realized in 21 cases, 
13 F (3%) and 8 M (5%) (p<0.83), node dissection was realized in 519 cases, 387 (79%) F 
vs 132 (78%) M (p<0.99), central node dissection in 434 cases, 340 (88%) F vs 94 (71%) 
M (p<0.75), laterocervical node dissection in 85 cases, 47 (12%) F vs 38 (29%) M 
(p<0.011), stage I was defined in 402 cases, 315 (64%) F vs 87 (51.5%) M (p<0.19), stage 
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II in 19 cases, 15 (3%) F vs 4 (2.5%) M (p<0.51), stage III in 180 cases, 126 (26%) F vs 54 
(32%)M (p<0.249), stage IV in  57 cases, 33 (7%) F vs  24 (14%) M (p<0.223), 
monofocality was in 368 cases, 279 (57%) F vs 89 (52.7%) M (p<0.64), plurifocality was 
in 290 cases, 210 (43%) F vs 80 (47.3%) M (p<0.76), tumor size was 14.13 mm (range 
0.5-80), it was 13.97 mm (range 1-80) in F vs 14.62 (range 0.5-70) in M (p<0.42), 
association with thyroiditis was observed in 157 cases, in 132 (27%) F vs 25 (15%) M 
(p<0.001), BRAF – V600E mutation was identified in 195 cases, 143 (29%) F vs 52 
(30.7%) M (p<0.849). 
We revised the follow up in 395 cases (60%). The mean time of follow up was 38 months 
(range 1-137),  37 months (range 1-343) in F vs 45  (range 4-156) in M (p<0.24),  342 
patients  underwent 
131
I radioiodinetherapy,  251 (88%) F vs 91 (83%) M (p<0.74), the 
median dose was 134.33 mCi (50-500), 132.63 mCi  (range 50-500) in F vs 139.42 mCi 
(range 50-350) in M (p<0.27), the median postoperative value of serum Tg level was 10.5 
mU/L (range 0.1-593),  7 mU/L (range 0.1-485.3) in F vs 19.83 (range 0.1-593) in M 
(p<0.11), 376 patients was free of disease, 274 (96%) F vs 102 (93.5%) M (p<0.64), 2 
patients deceased , 1  (0.2%) F vs 1 (1%) M (p<0.24). 
These findings are summarized on table 3. 
 
- Reproductive factors analyzed in women: 
Regarding hormonal profile in the women, relatively more advanced stage was correlated 
with early menarche, older age of first pregnancy, late menopause; moreover, a higher 
incidence of tumor was registered in childbearing age.  
These findings are summarized on table 4. 
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Table 3:  
Variables total Femaless Maless P value 
Number of patients 658 489 (74%) 169 (26%) p<0.015 
Age 46 (11-86) 46 (11-86) 46 (11-83) P<0.44 
Total thyroidectomy 635 474 (97%) 161 (95%) p<0.72 
Loboistmectomy 21 13 (3%) 8 (5%) p<0.83 
Node dissection 
Central compartment 
Lateral compartment 
519 
434 
85 
387 (79%) 
340 (88%) 
47 (12%) 
132 (78%) 
94 (71%) 
38 (29%) 
p<0.99 
p<0.75 
p<0.011 
TNM 
I 
II 
III 
IV 
 
402 
19 
180 
57 
 
315 (64%) 
15 (3%) 
126 (26%) 
33 (7%) 
 
87 (51,5%) 
4 (2,5%) 
54 (32) 
24 (14) 
 
p<0.19 
p<0.51 
p<0.249 
p<0.223 
monofocality 368 279 (57%) 89 (52,7) p<0.64 
plurifocality 290 210 (43%) 80 (47,3) p<0.76 
Tumor size in mm 14,13 
(0,5-80) 
13,97 (1-80) 14,62 (0,5-70) p<0.42 
Association with LCT 
(thyroiditis) 
157 132 (27%) 25 (15%) p<0.001 
BRAF mutation 
V600E 
WT 
 
195 
184 
 
143 (29%) 
142 ((29%) 
 
52 (30,7) 
42 (25%) 
 
p<0.849 
p<0.433 
Follow up 395(60%) 286 (58%) 109 (64%) p<0.18 
Time of follow up 38 (1-343) 37 months (1-
343) 
45 months (4-
156) 
p<0.24 
I
131
 radiotherapy 342 251 (88%) 91 (83%) p<0.74 
Dose 134,33 
mCi (50-
500) 
132,63 mCi (50-
500) 
139,42 mCi 
(50-350) 
p<0.27 
N° of radioiodine 
treatment 
1,13 (1-3) 1,09 (1-3) 1,23 (1-3) p<0.14 
TG levels 10,5 (0,1- 7 (0,1- 485,3) 19,83 (0,1- p<0.11 
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593) 593) 
Free of disease 376 274 (96%) 102 (93,5%) p<0.64 
Not free of disease 17 11 (3,8%) 6 (5,5%) p<0.76 
Deceased 2 1 (0,2%) 1 (1%) p<0.24 
  
 
Table 4: 
More aggressive stage was correlated with: (histotype and tumor diameter) 
Parameters 
Group A age <40 years 
Group B age > 40 years 
P value 
early menarche (stage III) P<0,026 
older age at first pregnancy (stage III) P<0,047 
late menopause (stage III) P<0.038 
> incidence of thyroid tumor in reproductive age (in group having < 40 years old)!!! 
 
Any correlation was found with the number f pregnancy, eventual interruption of 
pregnancy or with assumption of oral estrogen-progestin therapies. 
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- Evaluation of expression of ER- alpha and ER-beta receptors in thyroid tissue: 
In a little series of patients, we prospectively analyzed the perioperative serum level of 
estrogens and the expression of ER- alpha receptors and ER –beta by 
immunohistochemical studies in the sections of formalin-fixed tissue , paraffin-embedded 
tumor of the thyroid. 
We have immunohistochemically examined estrogen receptors (ER) on papillary thyroid 
carcinoma in 10 females. Of the specimens obtained from the 10 patients, 80% (8/10) 
showed positive staining for ER. 
Totally 10 patients, with a median age of 48 years (range: 31-77) were analyzed. Mean 
follow-up time was 3 months (range 1-12). Regarding the age, we have divided patients in 
two categories: young < 40 years old and > 40. 
We did not find any significant difference in the incidences of positive staining for E2 
between the two groups. 10 thyroid glands specimens have been examined using 
immunohistochemical assays with ERs alpha and beta antibodies. There was no expression 
of antibodies in non-neoplastic cells or in adjacent tissues.  
Tumor size ranged from 1,5 mm to 30 mm (median 13,5 mm).  Micro PTC (diameter < 
1cm) were found in 3 (30%) cases. BRAF mutation was present in 5 cases. 
Six patients underwent to central lymph node dissection (CLND). Of those, three (50%) 
had metastatic lymph nodes. Final histology showed the neoplasms to be in group A (<40 
years) 3 stage I and 2 stage III whereas in group B (>40 years old) there were 2 neoplasms 
stage I and three stage III  [p < 0,36]. 
The group A resulted composed by a more aggressive histological variants than group B 
(see table I)  and the tumor size was greater [p<0,0746].  
At the follow-up any neck recurrence occurred.  Mean serum postablative Tg levels after 
levothyroxine withdrawal resulted a little higher in group A (1,6 ng/mL vs 1,1 ng/mL) 
[p=N.S]. The mean radioactive iodine ablation doses was 142,63 mCi in group A vs 
139,42 mCi in group B [p= N.S]. 
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DISCUSSION 
 
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, accounting 
for approximately 80% of cases. Its incidence has nearly doubled over the last 30 years and 
is thought to be due in part to earlier diagnosis of subclinical disease [1- 6]. 
Diagnostic sensitivity and opportunities for detection have improved over the past decades 
with the introduction of thyroid ultrasound in the early 1980s and final-needle aspiration 
cytology in the late 1980s. Probably, these technologies could have potentially impacted 
the secular trends more in one gender than the other, but the gender disparities in PTC 
incidence is very high.  
Thyroid cancer incidence rates have increased worldwide for decades, although more for 
papillary carcinomas than other types and more for females than males.  
Cancer gender disparity in incidence, clinical presentation, disease aggressiveness, and 
prognosis has been observed for a variety of cancers [1-8]. 
There are few known thyroid cancer risk factors except female gender, and the reasons for 
the increasing incidence and gender differences are unknown. 
The pathogenesis of thyroid cancer is complex. Iodium deficiency, genetic factors, sex, 
older age, irradiation in childhood, thyroid growth stimulating antibodies and epithelial 
growth factor possibly affect its development. Recent reports, also epidemiological, have 
shown that differentiated thyroid cancer (papillary, follicular, oxyphillic) is dependent on 
sex hormones, especially estrogens. This has prompted research into the presence of 
estrogens and progesterone receptors (ER and PR), as well as androgen receptors (AR) in 
normal and neoplastic thyreocytes and estradiol content in thyroid tissue. The results of 
these investigations imply that thyroid cancers are estrogen-dependent. There is, however, 
no agreement in reports about correlation between tumor malignancy and ER, PR and AR 
expression. 
Several epidemiological studies have suggested a possible correlation between incidences 
of thyroid malignancies and hormones but the precise contribution of estrogen in thyroid 
proliferative disease initiation, and progression is not well understood [1-11] 
The rate of papillary thyroid cancer among woman is nearly three times higher than men, 
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with a widening gender gap over time [1,8].  
Kilfoy Briseis A. et Al [8] reported that the age-specific rates were higher among women 
than men across all age groups analyzed, and the female-to-male rate ratio declined quite 
consistently from more than five at ages 20–24 to 3.4 at ages 35–44 and approached one at 
ages 80+. These results confirmed that gender is an age-specific effect modifier for 
papillary thyroid cancer incidence. 
The less aggressive histologic subtypes of thyroid cancer are more common in women, 
whereas the more aggressive histologic subtypes have similar gender distribution. In 
females, the age-specific incidence rate rises sharply at the beginning of the reproductive 
years, with increasing age peaking at 40–49 years, while in men the peak is at 60–69 years 
[8]. The incidence rates equalize by 85 years of age [8,10-11]. Women have an earlier age 
of onset but men tend to have more aggressive disease at diagnosis. 
The gender disparity in incidence, aggressiveness and prognosis is well established for 
thyroid cancer but the origin of the disparity is poorly understood. 
Several causes as, radiation exposure, nutritional, genetic, molecular, reproductive, 
hormonal and environmental factors it has been hypothesized that may account for this 
difference [1-11]. 
As described by Rahbari R et al. [11] in the review of thyroid cancer gender disparity, 
regarding the ionized radiation exposure, it does not appear to play a role in the gender 
disparity of PTC, with both genders being at equal risk after exposure as demonstrated by 
Moysich Kb et al.[96]. 
As concerns the nutritional factors, in the San Francisco Bay Area Thyroid Cancer Study 
Group a protective effect of dietary iodine and phytoestrogens was found in women (608), 
but the study did not have any males subjects [13].  
Regarding the genetic factors, although some studies suggest BRAF - V600E mutation is 
more common in men [16] and this may be results in an more aggressive prognosis, a meta 
analysis of 12 studies with a total of 1168 patients didn’t show a significant difference in 
mutation rate by gender [18]. Basides, Sadetzki S et al. [97] described a higher rate of 
RET/PTC rearrangements in papillary thyroid cancer with male gender. About NTRK 
rearrangement, Brzezianska E. et al. analyzed the presence of an NTRK rearrangement and 
gender and no significant difference were found [98]. 
In our series BRAF - V600E mutation was identified in 29% of women and in 30.7% of 
men confirming the absence of significant difference among two sexes. 
In our series, although BRAF - V600E mutation was demonstrated to be an adverse 
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prognostic factor for the aggressiveness of the disease, but it not resulted independent from 
other clinical-pathological features in low-risk intrathyroid PTC patients, however it could 
be useful  in the workup of low-risk PTC patients, as supplementary prognostic factor to 
assess the preoperative risk stratification with the aim to avoid  unnecessary central neck 
node dissection and  complementary I
131
-terapy . 
Although thyroid cancer occurs much more frequently in females, the role of sex hormones 
in thyroid carcinogenesis is unknown.  
According to American Thyroid Association (ATA) [26], the incidences of thyroid 
proliferative diseases (TPD), which includes thyroid cancer, are four to five times more 
prevalent in women than in men. The risk of developing thyroid disorders in women is one 
in eight which is comparable to that of sporadic breast cancer in women, and is 
significantly enhanced with family history of endocrine-related diseases, age, use of oral 
contraceptives, autoimmune diseases and pregnancy. With respect to pregnancy, there is 
approximately 5% chance of developing a thyroid disorder in new mothers within 6 
months of birth. An increased risk is also noted with the use of estrogen for gynecological 
problems, with a noted decrease in the incidences of thyroid malignancies after menopause 
[11,30]. 
Several studies have been performed worldwide in an effort to investigate the role of 
estrogens in various cancers but the precise mechanism for estrogenopathies in TPDs 
remains poorly understood. 
There have been several studies looking at reproductive and hormonal factors and the risk 
of thyroid cancer with inconclusive results. The interpretation of these population-based 
studies is hampered by the fact that the rate of thyroid cancer varies dramatically among 
populations. The suggestion that the rates of thyroid cancer may differ due to reproductive 
and menstrual factors in these populations would support the hypothesis that these factors 
influence rates of thyroid cancer. However, based on clinical and epidemiology studies, 
there is no conclusive association between menstrual, reproductive or hormonal history 
with thyroid cancer risk. 
Hormonal differences are hypothesized to contribute to the approximately ≥2-fold higher 
thyroid cancer incidence rates among women compared with men worldwide [99]. As 
regards the hormonal factors, recently, several studies described the role of estrogens in the 
pathogenesis of thyroid cancer in women and it was confirmed that sex hormone effects 
are mediated by hormone specific nuclear receptors that regulate gene expression and 
tumor cell biology [27,28, 68 100 - 102].  
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Estrogen is known to promote the proliferation of thyroid papillary carcinoma cells. 
However, the molecular mechanism responsible is not well understood [68,70].  
The pattern of the subcellular localization of ER-alpha and ER-beta differs  between 
papillary and anaplastic cancer [68]. Upon E2 treatment, the level of ER-alpha increases in 
the nuclei of papillary cancer cells but ER-beta remains unchanged. The level of 
mitochondrial ER-beta surpassed that of ER-alpha in anaplastic cancer cells. The different 
locations of ER-alpha and ER-beta in PTC cells and in anaplastic carcinoma cells agreed 
with the finding that E2 promoted the proliferation of PTC but inhibited or did not affect 
that of ATC cells. Consequently, there are a differences  in epidemiology and responses to 
anti-tumour therapy between papillary and anaplastic cancer in terms of the subcellular 
localization of ER isoforms. 
Estrogen signaling is mediated primarily through two isoforms of the estrogen receptor 
(ER), ER-α and ER-β, which are members of a large ligand dependent nuclear receptor 
superfamily of transcriptional factors. 
The alpha and beta estrogen receptors (ER-α and ER-β) mediate the effect of estrogen and 
are expressed in PTC and it has been hypothesized that the polymorphism in estrogen 
receptors could be a risk factor for thyroid cancer [27,28, 68 100 - 102]. 
ER- α is predominantly expressed in breast, uterus, cervix, vagina, pituitary and several 
other organs including thyroid, while ER- β is predominantly expressed in ovary, prostate, 
testis, spleen, lung, hypothalamus, thymus. 
ER- α mRNA has also been reported in both non-neoplastic and neoplastic thyroid tissues. 
An imbalance between the expression of ER subtypes α and β has also been proposed to 
have significance with higher expression of ER- α promoting cell proliferation and growth 
while higher expression of ER- β promoting cell apoptosis in thyroid cancer cells. The 
presence of both ER- α and ER- β in thyroid tissue, similar to that observed in breast 
carcinoma, would suggest that the relative ratio of ER- α and ER- β in thyroid carcinoma 
could have an important role in the pathophysiology of thyroid cancer [61,65,68]. 
Kumar A et al. [68] demonstrated that the estradiol-induced proliferation of papillary and 
follicular thyroid cancer cells is mediated by ER-α and ER-β. 
Magri et al., using immunohistochemistry, evaluated ERα, ERβ, and AR expressions in 
thyroid tumors and in its correspondent extra-tumor parenchyma and concluded  that  ERα 
positivity, ERβ negativity, and Androgen Receptors expressions are associated with a more 
aggressive phenotype of small T1-differentiated thyroid carcinoma [103]. 
Hormonal differences are hypothesized to contribute to the approximately ≥2-fold higher 
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thyroid cancer incidence rates among women compared with men worldwide. Although 
thyroid cancer cells express estrogen receptors and estrogen has a proliferative effect on 
PTC cells in vitro, epidemiologic studies have not found clear associations between thyroid 
cancer and female hormonal factors. Schonfeld SJ et al. [99]  hypothesized that 
polymorphic variation in hormone pathway genes is associated with the risk of developing 
papillary thyroid cancer but the  pathway genes analyzed do not appeared to be strongly 
related to PTC risk. 
Concerning the reproductive factors, there have been few studies looking at reproductive 
and hormonal factors and the risk of thyroid cancer with inconclusive results [11,104]. 
Premenopausal women resulted at highest risk for papillary and follicular thyroid 
carcinoma, implicating a role for estrogens in thyroid cancer [68]. In our series, regarding 
the reproductive factors in the women, relatively more advanced stage was correlated with 
early menarche, older age of first pregnancy, late menopause; moreover, a higher incidence 
of tumor was registered in childbearing age stressing the role of estrogen to promoting the 
PTC. 
Moreover, our data confirm that, comparing males vs females, there was a significant 
difference concerning the number of patients affected by PTC with a preponderance of 
women. Also the number of central node dissection performed was dissimilar among the 
two groups of patients, in fact it was performed  in only 12% of females and in 29% of 
males confirming the major aggressiveness of this tumor in the men. The association with 
thyroiditis was most important in the women, whereas the others characteristics as age, 
TNM stage, mono and plurifocality, BRAF mutations, and outcome were not statistically 
diverse between two sexes.  
Recently, several studies aimed to evaluate the expression of estrogen receptors, α and β, in 
normal and malignant thyroid tissues and their effects on different molecular pathways 
involved in growth and function of the thyroid gland [101]. These studies opened up the 
possibility of developing alternative therapeutic treatments and preventive approaches 
which employ the use of antiestrogen to treat thyroid malignancies. 
Regarding the evaluation of  the expression of estrogen receptors, α and β, in normal and 
malignant thyroid tissues, we did not find any significant difference in the incidences of 
positive staining for E2 between the two groups of patients analyzed. 
In all specimen we find receptors ER-alpha and ER-beta. The presence of ER-alpha was 
major in patients who presented relative more aggressive stage but the results were non 
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statistically significant. It’s throw that we should consider that the time for evaluate the 
rate of recurrence was very low.  
Our preliminary results are in agreement with most available data. It seems, however, that 
the material so far examined by the investigators is too small. Furthermore, because of 
using various methods the results cannot be compared. Further studies are necessary to 
reveal if there is any true influence of sex hormones on the development of thyroid lesions 
and if the detection of sex hormone receptors may help in choosing adequate therapy. 
It was verified by Rajoria S. et al. that the estrogen induced metastatic modulators MMP-3 
and MMP-9 are targets of 3,3’diindolylmethane (DIM) in thyroid cancer. Furthermore, 
DIM, natural dietary compound found in cruciferous vegetables, displays anti-estrogenic 
like activity by inhibiting estradiol enhanced thyroid cancer proliferation [95].  
Moreover Rajora S. [30] in another review studied the estrogen activity as a preventive and 
therapeutic target in thyroid cancer. In this review there are the description of principal 
studies on estrogen receptors in thyroid tissue (table 5). 
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Table 5: Principal studies on estrogen receptors in thyroid tissue. [S. Rajora et Al. 
Biomedicine & Pharmacotherapy 66 (2012) 151–158]. 
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Family history of endocrine-related malignancies, such as breast cancer and goiter, are also 
known to predispose one to thyroid cancer. 
Somjen D. et Al., described the growth inhibition of human thyroid carcinoma and goiter 
cells in vitro by a novel isoflavone-derived anti-estrogenic compound developed in 
laboratory, the N-t-boc-hexylenediamine derivative of 7-(O)-carboxymethyl daidzein (cD-
tboc) [105].  
In this study we considered the clinical, histopathologic, molecular, and hormonal 
variables in our series of patients but our intention in the future is to evaluate the molecular 
and  genetic characteristics and the presence of estrogen receptors on  surgical specimens 
to identify also the possible medical targeted therapy for this type of tumor. 
A strong link between estrogen and thyroid cancer is still missing but the studies and 
findings reviewed here (summarized in table 6), open a potential new avenue and clinical 
utility for ER as a target for prevention and treatment of TPDs as well as a prototypical 
antiestrogen that can be used for therapeutic and preventive purposes of TPDs by not only 
suppressing the proliferation of thyroid cancer cells but also by inhibiting metastasis and 
angiogenesis associated events. This provides the foundation for multiple lines of 
investigation to elucidate estrogen’s biological functions in thyroid diseases, specifically in 
the evolution of an aggressive phenotype. The use of functional estrogen–ER antagonist 
that affects the multifaceted biological activity of estrogen in thyroid disease singly or in 
combination provide a reasonable therapeutic and secondary preventive option that is 
novel, effective and devoid of unwanted side effects. 
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Table 6: Molecular and cellular effects of estrogen on thyroid proliferative diseases. [S. 
Rajora et Al. Biomedicine & Pharmacotherapy 66 (2012) 151–158]. 
 
 
 
57 
 
 
CONCLUSIONS 
 
The incidence of thyroid cancer is increasing worldwide. Women of a reproductive age are 
at a threefold higher risk of developing thyroid cancer.  
Premenopausal women are at highest risk for papillary and follicular thyroid carcinoma, 
implicating a role for estrogens in thyroid cancer. 
The gender disparity in thyroid cancer incidence is age dependent. Although thyroid cancer 
is less common in men, they have a worse survival and more aggressive disease at 
presentation. 
The identification of mechanisms of carcinogenesis of PTC in women vs men is a really 
important and innovative step for the study of thyroid cancer. 
The rates of thyroid cancer differ across populations, yet the gender differences are 
uniformly observed among different regions and continents. Dietary and environmental 
factors do not appear to have a significant role in thyroid cancer gender disparity. Common 
somatic mutation in BRAF, RET/PTC and NTRK also do not account for the gender 
disparity in thyroid cancer.  
Clinical and epidemiologic studies show no consistent evidence in reproductive factors 
contributing to thyroid cancer gender disparity. 
Recent estrogen receptor-status studies in thyroid cancer cells demonstrate a difference in 
the receptor subtypes expressed based on the histology of thyroid cancer. Recent studies 
suggest estrogen and estrogen hormone receptor status in thyroid cancer cells may have a 
role in thyroid cancer progression. Moreover, the response to estrogen is dependent on the 
specific estrogen receptor expressed in thyroid cancer cells. 
In our opinion, oestrogen may play an important role as a promoting factor in the 
development of PTC. The role of estrogen in the progress of PTC, once identified the 
precise mechanisms and steps of tumorigenesis, could open up areas, as in breast cancer, of 
developing potential new medical antireceptorial therapies to prevent and treat thyroid 
malignancies. This indication needs further study. 
Our understanding of the environmental and genetic susceptibility for thyroid cancer will 
improve and can serve to help identify factors influencing thyroid cancer gender disparity. 
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